1-15 of 15
Bruce W. Konicek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping

Sau-Chi Betty Yan, Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, Wei Zeng, Bruce W. Konicek, Ling Liu, Volker Wacheck, Richard A. Walgren
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 528.
https://doi.org/10.1158/1538-7445.AM2017-528
Published: 01 July 2017
View article titled, Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping
Journal Articles

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Sau-Chi Betty Yan, Victoria L. Peek, Jennifer R. Stephens, Um L. Um, Amaladas Nelusha, Colleen A. Burns, Kelly M. Credille, Thompson N. Doman, Scott W. Eastman, Beverly L. Falcon, Gerald E. Hall, Philip W. Iversen, Bruce W. Konicek, Jason R. Manro, Any T. Pappas, Julie A. Stewart, Michael B. Topper, Swee-Seong Wong, Michael Kalos, Ruslan D. Novosiadly, Richard A. Walgren, David Schaer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5590.
https://doi.org/10.1158/1538-7445.AM2017-5590
Published: 01 July 2017
View article titled, Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model
Journal Articles

Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion

Bruce W. Konicek, Steve M. Bray, Andrew R. Capen, John N. Calley, Kelly M. Credille, Philip J. Ebert, Gary Heady, Bharvin K. Patel, Victoria L. Peek, Jennifer R. Stephens, Suzane L. Um, Melinda D. Willard, Isabella H. Wulur, Yi Zeng, Richard A. Walgren, Sau-Chi Betty Yan
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2647.
https://doi.org/10.1158/1538-7445.AM2016-2647
Published: 15 July 2016
View article titled, Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion
Journal Articles

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Sau-Chi Betty Yan, Suzane L. Um, Victoria L. Peek, Megan N. Thobe, Kelly M. Credille, Jennifer R. Stephens, Jason R. Manro, Darryl W. Ballard, Jessica A. Baker, Joel D. Cook, Bruce W. Konicek, Jeremy R. Graff, Timothy R. Holzer, Richard A. Walgren
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4403.
https://doi.org/10.1158/1538-7445.AM2014-4403
Published: 01 October 2014
View article titled, Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
Journal Articles

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.

Sau-Chi B. Yan, Megan N. Thobe, Bruce W. Konicek, Victoria L. Peek, Suzane L. Um, Richard A. Walgren, Huaxing Pei, Timothy P. Burkholder, Jeremy R. Graff
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3042.
https://doi.org/10.1158/1538-7445.AM2013-3042
Published: 15 April 2013
View article titled, Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2.
Journal Articles

Abstract LB-235: Sensitivity of diffuse large B cell lymphoma cells to Enzastaurin (LY317615.HCl) and its primary metabolite (LY326020) is critically dependent upon disruption of the eIF4F translation initiation complex

Ann M. McNulty, Chad A. Dumstorf, Chad A. Dumstorf, Stephen H. Parsons, Bruce W. Konicek, Chad A. Hall, Jeremy R. Graff
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): LB-235.
https://doi.org/10.1158/1538-7445.AM2012-LB-235
Published: 15 April 2012
View article titled, Abstract LB-235: Sensitivity of diffuse large B cell lymphoma cells to Enzastaurin (LY317615.HCl) and its primary metabolite (LY326020) is critically dependent upon disruption of the eIF4F translation initiation complex
Journal Articles

Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

Megan N. Thobe, Suzane L. Um, Victoria L. Peek, Darryl W. Ballard, Bruce W. Konicek, Kelly M. Credille, Philip J. Ebert, Gregory P. Donoho, S. Betty Yan
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2087.
https://doi.org/10.1158/1538-7445.AM2012-2087
Published: 15 April 2012
View article titled, Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method
Journal Articles

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

Bruce W. Konicek, Jennifer R. Stephens, Ann M. McNulty, Nathaniel Robichaud, Robert B. Peery, Chad A. Dumstorf, Michele S. Dowless, Philip W. Iversen, Stephen Parsons, Karen E. Ellis, Denis J. McCann, Jerry Pelletier, Luc Furic, Jonathan M. Yingling, Louis F. Stancato, Nahum Sonenberg, Jeremy R. Graff
Journal: Cancer Research
Cancer Res (2011) 71 (5): 1849–1857.
https://doi.org/10.1158/0008-5472.CAN-10-3298
Published: 01 March 2011
View article titled, Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases
Open the PDF for Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases in another window
Journal Articles

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

Jeremy R. Graff, Bruce W. Konicek, Rebecca L. Lynch, Chad A. Dumstorf, Michele S. Dowless, Ann M. McNulty, Stephen H. Parsons, Leslie H. Brail, Bruce M. Colligan, Jonathan W. Koop, Bernadette M. Hurst, James A. Deddens, Blake L. Neubauer, Louis F. Stancato, Harry W. Carter, Larry E. Douglass, Julia H. Carter
Journal: Cancer Research
Cancer Res (2009) 69 (9): 3866–3873.
https://doi.org/10.1158/0008-5472.CAN-08-3472
Published: 30 April 2009
View article titled, eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Open the PDF for eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival in another window
Includes: Supplementary data
Journal Articles

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

Jeremy R. Graff, Bruce W. Konicek, Julia H. Carter, Eric G. Marcusson
Journal: Cancer Research
Cancer Res (2008) 68 (3): 631–634.
https://doi.org/10.1158/0008-5472.CAN-07-5635
Published: 01 February 2008
View article titled, Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Open the PDF for Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy in another window
Journal Articles

Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts

Ann M. McNulty, Bruce W. Konicek, Rebecca L. Lynch, Donald Thornton, Larry Douglass, Bruce Colligan, Julia H. Carter, Jeremy R. Graff
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 314–315.
Published: 15 April 2006
View article titled, Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts
Journal Articles

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly Ross Hanna, Bruce W. Konicek, Rebecca L. Lynch, Spring N. Bailey, Crystal Banks, Andrew Capen, Robin Goode, Jason E. Lewis, Lillian Sams, Karen L. Huss, Robert M. Campbell, Philip W. Iversen, Blake Lee Neubauer, Thomas J. Brown, Luna Musib, Sandaruwan Geeganage, Donald Thornton
Journal: Cancer Research
Cancer Res (2005) 65 (16): 7462–7469.
https://doi.org/10.1158/0008-5472.CAN-05-0071
Published: 15 August 2005
View article titled, The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts
Open the PDF for The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts in another window
Journal Articles

Enzastaurin HCl (LY317615) suppresses GSK3β phosphorylation, induces apoptosis and suppresses growth of human colon cancer and glioblastoma xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna, Bruce W. Konicek, Rebecca L. Lynch, Spring N. Bailey, Crystal Banks, Drew Capen, Robin L. Goode, Jason E. Lewis, Lillian Sams, Blake L. Neubauer, Sandaruwan Geeganage, Don Thornton
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 157–158.
Published: 01 May 2005
View article titled, Enzastaurin HCl (LY317615) suppresses GSK3β phosphorylation, induces apoptosis and suppresses growth of human colon cancer and glioblastoma xenografts
Journal Articles

Depleting eIF4E expression with a novel eIF4E targeted antisense oligonucleotide suppresses eIF4E expression and human xenograft tumor growth without overt toxicity

Jeremy R. Graff, Bruce W. Konicek, Rebecca L. Lynch, Thomas M. Vincent, Spring N. Bailey, Phil Schwier, Drew Capen, Robin Goode, Sean Sissons, Karen Cox, Ann M. McNulty, Tao Wang, Lillian Sams, Sandaruwan Geeganage, Larry E. Douglass, Julia H. Carter, Eric G. Marcusson
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 135–136.
Published: 01 May 2005
View article titled, Depleting eIF4E expression with a novel eIF4E targeted antisense oligonucleotide suppresses eIF4E expression and human xenograft tumor growth without overt toxicity
Journal Articles

Eukaryotic translation initiation factor eIF-4E is consistently upregulated with human prostate cancer progression: Inhibition by siRNA or ASO therapy suppresses CaP xenograft growth.

Jeremy R. Graff, Bruce W. Konicek, Rebecca L. Lynch, Kimberly R. Hanna, Spring N. Bailey, Robin L. Goode, Ann M. McNulty, Mac A. Johnson, Blake L. Neubauer, Harry C. Carter, Thomas Vincent, Eric Marcusson, Bruce Colligan, Larry E. Douglass, Julia H. Carter
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 835–836.
Published: 01 April 2004
View article titled, Eukaryotic translation initiation factor eIF-4E is consistently upregulated with human prostate cancer progression: Inhibition by siRNA or ASO therapy suppresses CaP xenograft growth.